Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone

Molecular Therapy

Volumn 20, Issue 8, 2012, Pages 1550-1558

  Graversen, Jonas H ^a   Svendsen, Pia ^a,b   Dagnæs Hansen, Frederik ^b   Dal, Jakob ^b   Anton, Gabriele ^a   Etzerodt, Anders ^b   Petersen, Mikkel D ^b   Christensen, Peter A ^a,c   Møller, Holger J ^c   Moestrup, Søren K ^b,c  

^a Cytoguide ApS   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CD163 ANTIBODY DEXAMETHASONE CONJUGATE; CD163 ANTIGEN; DEXAMETHASONE SODIUM PHOSPHATE; HYDROCORTISONE; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BIOEQUIVALENCE; CELL TRANSPORT; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; ORGAN WEIGHT; RAT; SPLEEN WEIGHT; T LYMPHOCYTE; THYMUS WEIGHT; WEIGHT REDUCTION;

RATTUS;

EID: 84864550598     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.103     Document Type: Article

References (47)

1. Rhen, T and Cidlowski, JA (2005). Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353: 1711-1723.
2. McColl, A, Michlewska, S, Dransfield, I and Rossi, AG (2007). Effects of glucocorticoids on apoptosis and clearance of apoptotic cells. ScientificWorldJournal 7: 1165-1181.
3. Clark, IA (2007). How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 18: 335-343.
4. Saklatvala, J, Dean, J and Clark, A (2003). Control of the expression of inflammatory response genes. Biochem Soc Symp 70: 95-106.
5. Dayer, JM (2004). The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract Res Clin Rheumatol 18: 31-45.
6. Ghezzi, P and Cerami, A (2005). Tumor necrosis factor as a pharmacological target. Mol Biotechnol 31: 239-244.
7. Gordon, S (2007). The macrophage: past, present and future. Eur J Immunol 37 Suppl 1: S9-17.
8. Ardizzone, S and Bianchi Porro, G (2005). Biologic therapy for inflammatory bowel disease. Drugs 65: 2253-2286.
9. Sacre, SM, Andreakos, E, Taylor, P, Feldmann, M and Foxwell, BM (2005). Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med 7: 1-20.
10. Tincani, A, Andreoli, L, Bazzani, C, Bosiso, D and Sozzani, S (2007). Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun Rev 7: 1-7.
11. Magro, F and Portela, F (2010). Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 24 Suppl 1: 3-14.
12. Tansey, MG and Szymkowski, DE (2009). The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today 14: 1082-1088.
13. Taylor, PC and Feldmann, M (2009). Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5: 578-582.
14. Carter, PJ and Senter, PD (2008). Antibody-drug conjugates for cancer therapy. Cancer J 14: 154-169.
15. Kristiansen, M, Graversen, JH, Jacobsen, C, Sonne, O, Hoffman, HJ, Law, SK et al. (2001). Identification of the haemoglobin scavenger receptor. Nature 409: 198-201.
16. Schaer, DJ, Schaer, CA, Buehler, PW, Boykins, RA, Schoedon, G, Alayash, AI et al. (2006). CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 107: 373-380.
17. De Rycke, L, Baeten, D, Foell, D, Kruithof, E, Veys, EM, Roth, J et al. (2005). Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol 206: 17-27.
18. Komohara, Y, Hirahara, J, Horikawa, T, Kawamura, K, Kiyota, E, Sakashita, N et al. (2006). AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 54: 763-771.
19. Li, W, Xu, LH and Yuan, XM (2004). Macrophage hemoglobin scavenger receptor and ferritin accumulation in human atherosclerotic lesions. Ann N Y Acad Sci 1030: 196-201.
20. Moestrup, SK and Møller, HJ (2004). CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 36: 347-354.
21. Dijkstra, CD, Döpp, EA, Joling, P and Kraal, G (1985). The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 54: 589-599.
22. Polfliet, MM, Fabriek, BO, Daniëls, WP, Dijkstra, CD and van den Berg, TK (2006). The rat macrophage scavenger receptor CD163: expression, regulation and role in inflammatory mediator production. Immunobiology 211: 419-425.
23. Miksa, M, Das, P, Zhou, M, Wu, R, Dong, W, Ji, Y et al. (2009). Pivotal role of the alpha(2A)-adrenoceptor in producing inflammation and organ injury in a rat model of sepsis. PLoS ONE 4: e5504.
24. Karpurapu, M, Wang, X, Deng, J, Park, H, Xiao, L, Sadikot, RT et al. (2011). Functional PU.1 in macrophages has a pivotal role in NF-?B activation and neutrophilic lung inflammation during endotoxemia. Blood 118: 5255-5266.
25. Li, L, Whiteman, M and Moore, PK (2009). Dexamethasone inhibits lipopolysaccharide-induced hydrogen sulphide biosynthesis in intact cells and in an animal model of endotoxic shock. J Cell Mol Med 13(8B): 2684-2692.
26. Hattori, Y, Murakami, Y, Atsuta, H, Minamino, N, Kangawa, K, and Kasai, K. (1998). Glucocorticoid regulation of adrenomedullin in a rat model of endotoxic shock. Life Sci 62: PL181-PL189.
27. Ben Rhouma, K and Sakly, M (1994). Involution of rat thymus: characterization of cytoplasmic glucocorticoid receptors, evidence of glucocorticoid resistant dexamethasone receptor-positive cells. Arch Int Physiol Biochim Biophys 102: 97-102.
28. Rungruang, T, Chaweeborisuit, P and Klosek, SK (2010). Effect of malaria infection and dexamethasone on spleen morphology and histology. Southeast Asian J Trop Med Public Health 41: 1290-1296.
29. Zhang, Y, Croft, KD, Mori, TA, Schyvens, CG, McKenzie, KU and Whitworth, JA (2004). The antioxidant tempol prevents and partially reverses dexamethasoneinduced hypertension in the rat. Am J Hypertens 17: 260-265.
30. U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research. (2005). Guidance for Industry, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.
31. Mordenti, J (1986). Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75: 1028-1040.
32. Teicher, BA (2009). Antibody-drug conjugate targets. Curr Cancer Drug Targets 9: 982-1004.
33. Anderson, R, Franch, A, Castell, M, Perez-Cano, FJ, Bräuer, R, Pohlers, D et al. (2010). Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res Ther 12: R147.
34. Chono, S and Morimoto, K (2006). Uptake of dexamethasone incorporated into liposomes by macrophages and foam cells and its inhibitory effect on cellular cholesterol ester accumulation. J Pharm Pharmacol 58: 1219-1225.
35. Chono, S, Tauchi, Y, Deguchi, Y and Morimoto, K (2005). Efficient drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic mice. J Drug Target 13: 267-276.
36. Melgert, BN, Olinga, P, Van Der Laan, JM, Weert, B, Cho, J, Schuppan, D et al. (2001). Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats. Hepatology 34(4 Pt 1): 719-728.
37. Rensen, PC, Gras, JC, Lindfors, EK, van Dijk, KW, Jukema, JW, van Berkel, TJ et al. (2006). Selective targeting of liposomes to macrophages using a ligand with high affinity for the macrophage scavenger receptor class A. Curr Drug Discov Technol 3: 135-144.
38. Wijagkanalan, W, Higuchi, Y, Kawakami, S, Teshima, M, Sasaki, H and Hashida, M (2008). Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model. Mol Pharmacol 74: 1183-1192.
39. Morganelli, PM and Guyre, PM (1988). IFN-gamma plus glucocorticoids stimulate the expression of a newly identified human mononuclear phagocyte-specific antigen. J Immunol 140: 2296-2304.
40. Vallelian, F, Schaer, CA, Kaempfer, T, Gehrig, P, Duerst, E, Schoedon, G et al. (2010). Glucocorticoid treatment skews human monocyte differentiation into a hemoglobinclearance phenotype with enhanced heme-iron recycling and antioxidant capacity. Blood 116: 5347-5356.
41. Vos, JA, Abbondanzo, SL, Barekman, CL, Andriko, JW, Miettinen, M and Aguilera, NS (2005). Histiocytic sarcoma: a study of five cases including the histiocyte marker CD163. Mod Pathol 18: 693-704.
42. Yang, GC, Besanceney, CE and Tam, W (2010). Histiocytic sarcoma with interdigitating dendritic cell differentiation: a case report with fine needle aspiration cytology and review of literature. Diagn Cytopathol 38: 351-356.
43. Boven, LA, van Meurs, M, Boot, RG, Mehta, A, Boon, L, Aerts, JM et al. (2004). Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122: 359-369.
44. McCabe, C, Edlin, R and Round, J (2010). Economic considerations in the provision of treatments for rare diseases. Adv Exp Med Biol 686: 211-222.
45. Cox, TM (2010). Gaucher disease: clinical profile and therapeutic developments. Biologics 4: 299-313.
46. Garber, AM (1992). No price too high? N Engl J Med 327: 1676-1678.
47. Maniecki, MB, Etzerodt, A, Moestrup, SK, Møller, HJ and Graversen, JH (2011). Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression. Immunobiology 216: 882-890.